Article
Liquid Biopsy, ctDNA Diagnosis through NGS
28 Aug 2021
Abstract excerpt
Liquid biopsy with circulating tumor DNA (ctDNA) profiling by next-generation sequencing holds great promise to revolutionize clinical oncology. It relies on the basis that ctDNA represents the real-time status of the tumor genome which contains information of genetic alterations. Compared to tissue biopsy, liquid biopsy possesses great advantages such as a less demanding procedure, minimal invasion, ease of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
